AbbVie Acquires Apogee Therapeutics for $10.9 Billion in Eczema Bet
AbbVie is snapping up Apogee Therapeutics, a biotech developing an experimental eczema treatment, in a $10.9 billion deal.
AbbVie announced Monday it will acquire Apogee Therapeutics for $10.9 billion, placing a massive wager on an experimental drug targeting atopic dermatitis — the chronic inflammatory skin condition commonly known as eczema. The deal instantly vaulted Apogee into the spotlight as one of the year's most significant biotech acquisitions.
Shares of Apogee surged nearly 47% by Monday's close, reflecting investor confidence that AbbVie's offer represented a substantial premium for a company still in the experimental stage. The dramatic single-day gain underscores how fiercely pharmaceutical giants are competing to secure next-generation treatments in the crowded but lucrative dermatology space.
Read more Tim Cook Warns of Rising iPhone Costs Due to Memory Prices →
For AbbVie, the transaction represents a strategic push to diversify its portfolio beyond its flagship anti-inflammatory drug Humira, which has faced mounting biosimilar competition since losing patent exclusivity. Atopic dermatitis is a high-priority therapeutic area, and landing a promising pipeline asset could help AbbVie defend and expand its immunology dominance in the years ahead.
The deal also highlights the broader consolidation wave reshaping the biotech industry, as large pharmaceutical companies with deep balance sheets increasingly look to acquire innovative smaller firms rather than develop every compound internally. Apogee's experimental atopic dermatitis drug, if it clears clinical and regulatory hurdles, could emerge as a significant competitor in a market where existing therapies already generate billions in annual revenue.
Continue reading at MarketWatch.com
